Gestational Diabetes Market Report 2026

The gestational diabetes market size has grown strongly in recent years. It will grow from $9.11 billion in 2025 to $9.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing obesity rates, higher maternal age pregnancies, early diabetes screening programs, growth in prenatal care services, awareness of pregnancy complications.

The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $13.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising gestational diabetes prevalence, expansion of digital health monitoring, improved prenatal diagnostics, focus on preventive maternal care, healthcare policy support. Major trends in the forecast period include rising adoption of blood glucose monitoring, increased use of insulin therapy during pregnancy, growing focus on lifestyle-based disease management, expansion of prenatal screening programs, improved maternal health awareness.

The rising obese population is expected to drive the growth of the gestational diabetes market in the coming years. Obese individuals are those with a body mass index (BMI) of 30 or higher, indicating excess body fat that can pose serious health risks. The increase in obesity is driven by factors such as sedentary lifestyles, higher consumption of calorie-dense processed foods, genetic predispositions, and limited access to healthy diet and exercise options. Managing gestational diabetes is particularly important for obese pregnant women, as they face higher risks of insulin resistance and excessive weight gain, which can lead to complications for both mother and baby if untreated. For example, in May 2025, the Office for Health Improvement and Disparities, a UK government agency, reported that from 2023 to 2024, approximately 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64% in 2022-2023. Therefore, the growing obese population is fueling the gestational diabetes market.

Key companies in the gestational diabetes market are focusing on developing advanced diagnostic solutions for early detection of the condition. Diagnostic kits for gestational diabetes measure blood glucose levels to detect abnormal glucose tolerance in pregnant women, enabling timely intervention and management. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology firm, launched the XpressGT RUO kit, designed to diagnose gestational diabetes, endometriosis, insulin resistance, and liver disease. The kit measures 2-hydroxybutyrate (2-HB) levels in venous blood, which are naturally produced by the liver. Elevated 2-HB levels are associated with increased reductive stress, linked to endocrine and obesity-related disorders including insulin resistance. Compatible with standard clinical analyzers, the kit provides results in just 8 minutes, offering a rapid and efficient diagnostic solution.

In April 2024, Digostics, a UK-based provider of diabetes home-testing solutions, partnered with AgaMatrix Europe to enhance gestational diabetes screening. Through this partnership, AgaMatrix will exclusively distribute Digostics’ home oral glucose tolerance test (OGTT) service, GTT@home, to the UK National Health Service (NHS). Leveraging its established NHS relationships and expertise in gestational diabetes monitoring, AgaMatrix aims to accelerate the service’s introduction across UK maternity services. AgaMatrix Europe is a UK-based manufacturer of blood glucose monitoring solutions.

Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd.

North America was the largest region in the gestational diabetes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gestational diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gestational diabetes market by increasing costs of imported insulin, glucose monitoring devices, and diagnostic kits. Hospitals and maternity clinics are most affected due to reliance on imported medical supplies. These tariffs raise care costs by increasing expenses for insulin therapy, continuous glucose monitoring, and routine screening during pregnancy, potentially affecting access to timely maternal care. However, they encourage local production of diabetes management products, supporting domestic manufacturing of insulin formulations, testing kits, and monitoring devices.

The gestational diabetes market research report is one of a series of new reports that provides gestational diabetes market statistics, including gestational diabetes industry global market size, regional shares, competitors with a gestational diabetes market share, detailed gestational diabetes market segments, market trends and opportunities, and any further data you may need to thrive in the gestational diabetes industry. This gestational diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gestational diabetes is a form of diabetes that arises during pregnancy when the body is unable to produce sufficient insulin to maintain proper blood sugar levels. It usually develops in the second or third trimester and can affect women with no prior history of diabetes. Gestational diabetes carries risks for both mother and baby, including high birth weight, preterm birth, and an increased likelihood of developing type 2 diabetes later in life for both. Management typically involves dietary modifications, exercise, blood sugar monitoring, and sometimes insulin therapy to support a healthy pregnancy and delivery.

The main types of gestational diabetes include type A1, type A2, and other forms. Gestational diabetes Type A1 is a type of diabetes that occurs during pregnancy and falls under gestational diabetes mellitus (GDM), which happens when the body cannot produce enough insulin to meet the increased demands of pregnancy. Treatments include monitoring, pharmacological therapy, and non-pharmacological interventions, administered orally, intravenously, or via other routes. These treatments are used in hospitals, clinics, home care settings, and diagnostic centers.

The gestational diabetes market consists of revenues earned by entities by providing services such as nutritional counseling, medication management, telemedicine services, lifestyle and exercise guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational diabetes market also includes sales of metformin, glyburide, and insulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.